Thoroughbred Financial Services LLC lifted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 14.3% in the second quarter, according to its most recent filing with the SEC. The firm owned 17,592 shares of the company’s stock after acquiring an additional 2,200 shares during the period. Thoroughbred Financial Services LLC’s holdings in Teva Pharmaceutical Industries were worth $285,000 as of its most recent filing with the SEC.
Other institutional investors have also made changes to their positions in the company. New Covenant Trust Company N.A. bought a new position in Teva Pharmaceutical Industries during the first quarter worth about $28,000. EntryPoint Capital LLC bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth approximately $30,000. Beach Investment Counsel Inc. PA acquired a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at $48,000. Byrne Asset Management LLC bought a new stake in Teva Pharmaceutical Industries in the second quarter valued at $52,000. Finally, Industrial Alliance Investment Management Inc. acquired a new position in Teva Pharmaceutical Industries during the first quarter worth $54,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other news, insider Eric A. Hughes sold 24,537 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the transaction, the insider now directly owns 45,060 shares in the company, valued at approximately $777,285. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.55% of the stock is currently owned by company insiders.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Price Performance
Teva Pharmaceutical Industries stock opened at $17.85 on Wednesday. The stock has a market cap of $20.22 billion, a price-to-earnings ratio of -43.54, a P/E/G ratio of 1.26 and a beta of 0.88. Teva Pharmaceutical Industries Limited has a 12-month low of $8.06 and a 12-month high of $19.08. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. The business’s 50-day simple moving average is $17.63 and its 200 day simple moving average is $16.02.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The business had revenue of $4.16 billion during the quarter, compared to the consensus estimate of $3.99 billion. As a group, research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current year.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Recommended Stories
- Five stocks we like better than Teva Pharmaceutical Industries
- Consumer Staples Stocks, Explained
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Investing In Automotive Stocks
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- With Risk Tolerance, One Size Does Not Fit All
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.